TXG - 10x Genomics GAAP EPS of -$0.15 beats by $0.17 revenue of $156.2M beats by $8.03M
- 10x Genomics press release ( NASDAQ: TXG ): Q4 GAAP EPS of -$0.15 beats by $0.17 .
- Revenue of $156.2M (+8.9% Y/Y) beats by $8.03M .
- 2023 Financial Guidance
- 10x Genomics expects full year 2023 revenue to be in the range of $580 million to $600 million vs $613.96M consensus, representing 12% to 16% growth over full year 2022 revenue.
For further details see:
10x Genomics GAAP EPS of -$0.15 beats by $0.17, revenue of $156.2M beats by $8.03M